US FDA Drafts Guidance On Responding To Cybersecurity Threats
This article was originally published in Clinica
Executive Summary
The US FDA has issued a draft guidance on how companies should monitor and respond to potential cybersecurity threats in the postmarket setting.
You may also be interested in...
'Sharing' Organizations Stay In Final Post-Market Cybersecurity Guidance
Despite pushback from industry groups on the use of information-sharing and analysis organizations (ISAOs), US FDA has kept the language the same in its final post-market cybersecurity guidance, but has removed the term "essential clinical performance."
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.